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Abstract 
The extracorporeal carbon dioxide removal concept, used as an integrated tool with conventional 
ventilation, plays a role in adjusting respiratory acidosis consequent to Tidal Volume (Vt) reduction 
in protective ventilation setting.  
This concept arises from the ECMO experience and from this originates.  Kolobow and Gattinoni 
were the first in introducing extracorporeal support, with the intent to separate carbon dioxide 
removal from oxygen uptake; they hypothesized that, to allow the lung to “rest”, oxygenation via 
mechanical ventilation could be dissociated from decarboxylation via extracorporeal carbon 
dioxide removal. 
Carbon dioxide is removed by a pump-driven modified ECMO with veno-venous bypass, while 
oxygenation is accomplished by high levels of positive end-expiratory pressure, with a respiratory 
rate of three to five sighs every minute. The focus was that, in case of acute respiratory failure, CO2 
extraction facilitates a reduction in ventilatory support and oxygenation is maintained by simple 
diffusion across the patient’s alveoli, called “apneic oxygenation”. 
Concerns have been raised regarding the standard use of extracorporeal support because of the 
high incidence of serious complications: hemorrhage, hemolysis and neurological impairments. 
Due to the negative results of a clinical trial, the extensive amount of required resources and the 
high incidence of side effects, LFPPV-ECCO2R was restricted to a “rescue” therapy for the most 
severe case of ARDS.  
Technological improvement led to the implementation of two different CO2 removal approaches: the 
iLA called “pumpless arterio-venous ECMO” and the Veno-venous ECCO2R. They allow to 
considerate the extracorporeal support as something more than a mere rescue therapy; both of 
them are indicated in more protective ventilation settings in case of severe ARDS, and as a support 
to the spontaneous breathing/lung function in bridge to Lung transplant. 
Is foreseeable the future development of more and more efficient devices capable of removing a 
substantial amount of carbon dioxide production (30–100%), with blood flows of 250–500 ml/min. 
Moreover the future ARDS management should include a minimally invasive extracorporeal carbon 
dioxide removal circuit associated with a noninvasive ventilation. This would embody the modern 
mechanical ventilation philosophy: avoid tracheal tubes, minimize sedation and prevent ventilator-
induced acute lung injury and nosocomial infections. 
  
 
Introduction 
Since 1979 it is possible to markedly hypoventilate the lung at a rate of 2 to 4 breaths/minute 
or allow spontaneous but insufficient ventilation still maintaining normal arterial blood gases, while 
the metabolically produced CO2 is removed by an extracorporeal membrane lung and the oxygen is 
fed through a tracheal tube or an helmet with a Continuous Positive Airways Pressure (CPAP). [1,2] 
In 2001 the NIH published a randomized controlled trial that recommended to ventilate acute 
respiratory distress syndrome (ARDS) patients with a tidal volume (Vt) of 6 ml/kg (predicted body 
weight) and a maximum end-inspiratory plateau pressure (Pplat) of 30 cm H2O, in order to prevent 
a ventilation lung damage.[4]  Recently published studies show that despite these limitations, a tidal 
hyperinflation may occur in about the 30% of ARDS patients; furthermore they may benefit from 
Vt reduction even if they already have a Pplat < 30cm H2O.[5,6]   
Those results support the concept of extracorporeal carbon dioxide removal concept as 
integrated to conventional ventilation to adjust respiratory acidosis consequent to very low Vt, and 
therefore allowing a more protective ventilator settings.[7]This approach might also reduce 
ventilator induce lung jniury (VILI) that is one of the most important and actual problem in 
diseased lungs and allow a wider clinical implememtation of the new concept “ less ventilation, less 
injury”.[3] 
 
Extracorporeal CO2 removal: the concept  
The basic concepts of the CO2 removal technique, can be extracted from the original 
description of extracorporeal membrane oxygenation (ECMO) that appeared in the clinical setting 
more than 30 years ago.  In those years, Hill et al. reported for the first time the successful use of 
extracorporeal circulation to treat acute hypoxemic respiratory failure in an adult patient [8]; Barlett 
demonstrated for the first time the successful use of ECMO in a neonate [9].  
 
In the same period, studies published by Kolobow and Gattinoni introduced extracorporeal 
support intended to separate carbon dioxide removal from oxygen uptake.[10]  Extra-Corporeal 
CO2Removal (ECCO2R) refers to an extracorporeal support, focused on the removal of blood CO2, 
rather than on the improvement of the oxygenation.  Extra-corporeal oxygenation was initially 
designed as a heart-lung machine to render major cardiovascular surgery feasible and safe; this 
  
application was not that far from the one suggested by Kolobow and Gattinoni for the acute 
respiratory failure. The blood flow levels required to obtain a carbon dioxide removal, are lower 
than the ones needed to achieve the oxygenation so Kolobow exploited the concept that, if CO2 is 
removed by a membrane lung through a low flow high ventilation venovenous bypass, it is possible 
to reduce the ventilatory support in acute respiratory failure and severe ARDS, maintaining 
oxygenation simply with patient’s alveoli diffusion, also called “apneic oxygenation”[10], allowing 
the lung rest. Originally the veno-venous bypass was set out via the cannulation of the common 
femoral and the jugular veins, through a surgical cut; the larger lumen needed to be used for venous 
drainage, the smaller for blood return (toward the tricuspid valve minimizing the recirculation). 
Wounds and multiple cannulations determined continuous blood oozing and nursing care and 
patient mobility limitations, therefore the same authors developed a double lumen femoral vein 
cannulation technique; with the introduction of newly designed percutaneous cannulas and the 
Seldinger’s technique, we arrive to nowadays technique.  The first membrane lungs consisted of 
microporous polypropylene fibers and were associated to constant plasma leakage, that determined 
a frequent need for membrane substitution and the circuit needed to be heparinized with 100 IU/kg 
at the cannula insertion.  Heparin infusion was hence titrated on Activated Clotting Time (150-200 
sec).  
Gattinoni, using this modified ECMO technique (LFPPV- ECCO2R), reported an ARDS 
survival up to 49%. [10] that was also attributed to patient selection, strict control of coagulation, 
and ventilator management directed to reach the “lung rest”.[10,11] Anderson et al. in 1993, 
demonstrated a 47% survival in adults with severe respiratory failure. In a retrospective review of 
100 adult patients, Kolla et al. reported a 54% overall survival. [12]  However, despite the later 
report from Brunet that used LFPPV- ECCO2R to improve oxygenation, reducing pulmonary 
barotrauma in ARDS and achieving a mortality rate of 50% [13], in 1994 Morris et al. presented 
the results of a randomized clinical trial where he use of “conventional” Pressure Controlled 
Inverse-Ratio ventilation was compared to ECCO2R in ARDS patients;  the study showed no 
significant difference in survival between the two interventions and reported several episodes of 
severe bleeding. [14] Extracorporeal carbon dioxide removal was hence restricted to the sickest 
patients in whom all other treatments had failed and limited only to the centers with large 
expertise.[15] 
 
At the present time, ECMO, (Figure 1) with the news technologies, (centrifugal blood pump 
and news polymethylpentene low-resistance diffusion membrane oxygenators) still performs very 
well in maintaining oxygenation and eucapnia in the most severe ARDS patients with refractory 
  
hypoxemia.[16] In this application, a higher than 50% survival can be achieved, whereas sepsis and 
multiple organ failure are the leading causes of unsuccessful use.  Only a minority of the patients 
suffers major complications related to the technique itself, and that serious complications are almost 
exclusively related to bleeding (particularly intracranial bleeding)[17]. 
 
Extracorporeal CO2 removal: the clinical data  
The removal of “only a portion of carbon dioxide production” was originally developed by 
Pesenti et al., and has been recently implemented with new devices that may reduce side effects, 
complexity, and costs of extracorporeal carbon dioxide removal[18].  In 1983, Ohtake described a 
simple method to remove carbon dioxide using the arterial blood pressure in an arterio-venous 
setting including an hollow fiber oxygenator: the “pumpless arterio-venous ECMO”.[19] 
The system was characterized by a new membrane gas exchange system based on an heparin-
coated hollow fiber technology, that optimized blood flow reducing the resistances and that was 
connected to the patient via arterial and venous cannulae inserted with Seldinger’s technique.  
The device did not required extended technical and staff support: blood flow is determined by the 
driving force given by the cardiac output, and the mean arterial pressure: twenty to twenty-five 
percent of the cardiac output pass as left to right shunt  (an ultrasound flow meter might indicate the 
amount of blood passing per minute).  Furthermore, the system used a “low-dose” heparin infusion 
that did not exceed normal antithrombotic anticoagulation of the intensive care patient. 
 
These findings conducted to the newly designed Interventional Lung Assist (iLA) device.  
Bein et al. recently reported a retrospective analysis of 90 patients with critical 
hypoxemia/hypercapnia treated with iLA device, who, despite ventilation with low VT (320–
470ml), showed physiologic values of Pa CO2 (31–42 mmHg) and pH (7.38 –7.50)[20].  However, 
the authors reported a complication rate of 24%, including limb ischemia, compartment syndrome, 
and intracranial hemorrhage. In addition, continuous intravenous norepinephrine infusion was 
needed to maintain an artero-venous pressure gradient. 
In 2008 Fisher and coll. described the iLA new concept of protective ventilation as a bridge to 
lung transplant (LTx): in the Hannover experience twelve patients  who developed severe 
ventilation-refractory hypercapnia and acidosis despite maximal conventional ventilatory support 
received iLA implantation, obtaining a Pa CO2 levels reduction and a significant improvement in 
pH values. [21] In a recent study, Zimmermann implemented an iLA system  in 51 ARDS patients 
suffering from persistent hypoxaemia and/or hypercapnia, unresponsive to conventional therapy 
  
achieving a de-escalation of invasive ventilatory variables preventing ventilator induced lung injury 
[22]. 
Although  iLA is a simple device that can be established quickly, and has an easy monitoring, 
an arterial cannulation is always required, which can not be performed in  patients with serious 
peripheral arterial disease and has the potential risk to induce limbs ischemia . Additionally, the 
only system driving force is the patient’s heart and frequently it is necessary a continuous 
intravenous norepinephrine infusion, in order to maintain an artero-venous pressure gradient. 
 
In the last years, a new concept of CO2 removal device was experimented to reduce 
complexity, side effects and expenses of extracorporeal lung assistance.  Livigni and coworkers, 
described in animal model the efficacy and safety of a veno-venous device (ECCO2R) with a low-
flow CO2 removal system.[23] In 2009 Terragni at al. studied the effects of further Vt decreasing in 
a group of ARDS patients who developed plateau pressures of 28–30 cm H2O. The tidal volume 
was decreased to 4 ml/kg of predicted body weight (PBW), and the predictable consequence of 
increase in PaCO2 was corrected through an extracorporeal circuit. The intervention was safe and 
produced notable physiologic improvements.[7] 
 
This new generation ECCO2R consists of modified standard continuous veno-venous 
hemofiltration setup (Decap®, Hemodec, Salerno, Italy) that includes, in series with the hemofilter 
an oxygenator.  This system is less invasive since the veno-venous circuit is accessed via a double 
lumen catheter through a femoral vein, and the blood flow is driven through the circuit by a roller 
non-occlusive low-flow pump through a membrane lung that is connected to a fresh gas flow source 
delivering 100% oxygen. Exiting the membrane lung, blood is driven to an hemofilter. The 
resulting plasmatic water is re-circulated through the membrane lung by a peristaltic pump. The 
membrane lung and the hemofilter are coupled in series in order to increase the pressure inside the 
membrane lung by adding the downstream resistance exerted by the hemofilter and therefore 
reducing the risk of air bubble formation, minimizing the need for heparin by diluting the blood 
entering the membrane lung by re-circulating the plasmatic water separated by the hemofilter, and 
enhancing the performance of the extracorporeal device extracting the carbon dioxide dissolved in 
the plasmatic water separated by the hemofilter and re-circulated through the membrane lung. [7]  
Pietropaoli and coworkers described the use of this new generation ECCO2R to assist a patient 
affected by primary graft dysfunction after a single lung transplantation. Although this system 
should not be considered a replacement for traditional ECMO, because the performances are not 
comparable in terms of CO2 removal and especially oxygenation improvement, available data 
  
suggest that this “mini-ECMO” optimize pH values, reduce partial pressure of CO2 allowing to 
minimize ventilatory support and therefore minimizing VILI with no adverse events in terms of 
bleeding, circuit clotting, severe hemodynamic instability, or venous embolism[24]. 
 
 
Extracorporeal CO2 removal: the technological development 
Extracorporeal circulation can be achieved using an oxygenator for the CO2 removal from its 
dry form (dissolved CO2) or an hemodialyser for CO2 removal from its wet form [7,23, 25,26]. 
In the artificial lung, the real limiting factor of CO2 elimination is physiological. The reaction 
speed of bicarbonates dehydration, and the consecutive rise in the CO2 concentration in plasma, are 
very slow. This explains the need to bypass the 25% of the cardiac output in order to eliminate 
metabolic CO2 production.  Oxygenator associated acidification and hamolidialyzer associated 
alkalinisation are methods that facilitate the shifting of the bicarbonate/dissolved CO2 equilibrium 
in the sense respectively of dissociation (CO2 partial pressure raised) or of hydration (bicarbonate 
raised).  Even if the efficacy of CO2 removal through hemodialysis (with or without NaOH 
dialysate alkalinisation) was higher than the CO2 elimination obtained through an oxygenator  (with 
or without inlet HCL blood acidification)[25], the latter (without blood acidification) is today the 
most followed by clinicians in severe ARF because of the reduction in the circuit complexity. At the 
present time, only preliminary data are available from the Pesenti and coworkers about the effects 
of blood acidification to enhance carbon dioxide removal of Membrane Lung (ML) in swine model. 
In this study, the authors demonstrates that blood acidification at the inlet of a ML can significantly 
increase the CO2 removal by the ML by converting the blood bicarbonate into physically dissolved 
CO2. (29-30) 
For most adult patients with unresponsive severe respiratory failure, veno-venous support is 
the method of choice, including both extracorporeal CO2 removal (ECCO2R) and veno-venous 
ECMO (VV ECMO).  If the need of extracorporeal ventilatory support is partial, new generation of 
ECCO2R devices that uses arterial-venous pump-less bypass or low flow venous-venous bypass that 
can remove only the 20-30 % of CO2 production are available in clinical practice. [7,24,26] 
1. V-V ECMO 
Extra-Corporeal CO2 Removal refers to an extracorporeal support focused on the CO2 
leaching from blood rather than improving oxygenation [1,28]. In cases of  hypoxic/hypercapnic 
respiratory failure, but preserved cardiac function, a veno-venous extracorporeal membrane 
oxygenation (V-V ECMO) support is  preferred to carry over the pulmonary function.  
  
Centrifugal pumps and surface-heparinized (Bioline coating) hollow fiber membrane lungs 
both mounted on a specially designed multifunctional holder represent the state of the art. A flow 
meter and a bubble sensor are integrated into the pump unit. Tubing circuit consists of a pre-
connected, heparin-coated closed-loop extracorporeal circulation system for rapid setup and 
priming. Total priming volume is 600 ml of normal saline. The centrifugal pump provides non-
pulsatile flow rates of up to 4.5 L/min (depending on the size of the cannula). The circuit needs to 
be heparinized with 100 IU/kg at the cannula insertion, heparin infusion is titrated on Activated 
Clotting Time (ACT) of 150-200 sec but in surface-heparinized, the circuit can work well without 
any systemic anticoagulation for at least 12-48 hrs [29]. Before cannulation, usually performed with 
a modified Seldinger technique, ultrasonic measurement of the femoral vessels is performed to 
assess the appropriate calibre of cannula. Depending on the ultrasonic findings and the patient’s 
biometric data, a 17 or 23 Fr cannula  must be inserted for venous and a 15 or 17 Fr cannula for 
arterial vascular access. Outflow is achieved via the femoral vein, and inflow is gained by 
cannulation of the internal jugular vein or femoral vein and thereafter into the superior vena cava. 
2. Pumpless Arterio-Venous interventional Lung Assist (iLA)  
The interventional Lung Assit (iLA, NovaLung GmbH, Hechingen, Germany) is a single-use 
compact extrapulmonary gas exchange system perfused by passive femoral artery-femoral vein 
shunt, generated by the arterial blood pressure (60-80 mmHg femoral artery-femoral vein) through 
a lung assist device; a blood flow rate of approximately 1.0–2.5 L/min produces an effective CO2 
extraction and an improvement in arterial oxygenation. Apart from an oxygen supply (10–12 
L/min), the system does not require additional energy or substrate sources.[20] (Figure 2)  A 
polymethylpentene diffusion membrane resistant to plasma leakage is used as a separation layer 
between phases (blood/gas), due to the molecular structure of this layer, the passage of air bubbles 
from gas to the blood path in the event of negative pressure on the blood side is impossible. The 
entire effective gas exchange surface area amounts to 1.3 m2, integration of a heat exchanger is not 
necessary as temperature loss due to convection is negligible. To optimize hemocompatibility, the 
system is entirely (tip to tip) homogeneously treated with the coating method (Novalung Coating, 
NovaLung GmbH, Hechingen, Germany).  
To connect the iLA to the patient, a special percutaneous cannulation system has to meet the 
following conditions: implantable with Seldinger technique, cannulae walls extremely thin to 
minimize resistance to flow and availability in various diameters (13–21 Fr). In every individual 
case, the cannula size used is determined by the diameter of the vessel to be cannulated and the 
required shunt flow, diameter should be measured by ultrasound. Functional control is achieved 
  
through a monitoring doppler device. The weaning from iLA is attempted by reduction in 
mechanical ventilation and gas supply to approximately 1 L/min performed for 30 mins.  
The frequency of complications reported is actually very high: about 25% serious 
complications were observed; episodes of ischemia of a lower limb after arterial cannulation were 
major problems, in other cases of ischemia, the cannulae were removed and normal perfusion of the 
limb was restored. Cannula thrombosis was only observed in the early period without specially 
designed cannulae before 2001.  The main contraindication for the application of the system is a 
hemodynamic depression.[27] It is also reported the application of iLA as a bridge to Lung 
Transplant as presented by Fischer with the Hannover experience.[21] 
 
3.  Low flow ECCO2R technique  
The Decap® (Hemodec, Salerno, Italy) ECCO2R device is a modified renal replacement 
circuit incorporating a neonatal membrane lung coupled in series with a hemofilter.(Figure 3) 
Vascular access is granted by femoral vein and via a double lumen catheter 14 Fr diameter, inserted 
with the Seldinger technique; blood flow is driven by a roller non-occlusive low-flow pump 
(maximum flow 450 ml/min) through a membrane lung connected to a fresh gas flow source 
delivering 100% oxygen at a constant rate of 6 L/min. Exiting the membrane lung, blood is driven 
to an hemofilter and the resulting plasmatic water is made re-circulate through the membrane lung 
by a peristaltic pump (0–155 ml/min). Detectors of leaks and bubbles are inserted within the circuit. 
The circuit, including the membrane lung is primed with saline with a volume that ranges between 
140 and 160 ml. The new concept introduced by this newly designed technique is that the 
membrane lung and the hemofilter are coupled in series. This characteristic of the circuit increases 
the pressure inside the membrane lung by adding the downstream resistance exerted by the 
hemofilter and therefore reduces the risk of air bubble formation; minimizes the need for heparin by 
diluting the blood entering the membrane lung by recirculating the plasmatic water separated by the 
hemofilter; produces a performance enhancement of the extracorporeal device extracting the carbon 
dioxide dissolved in the plasmatic water separated by the hemofilter and recirculated through the 
membrane lung. [7,23,24,26] 
 
Extracorporeal CO2 removal: the future  
The NIH protocol represents the standard for mechanical ventilation of acute respiratory 
distress syndrome (ARDS) patients, recommending the use of low Vt of 6 ml/kg (predicted body 
  
weight) and an end-inspiratory plateau pressure of a maximum of 30 cm H2O.[4]  Despite these 
ventilatory limitations, tidal hyperinflation may occur in up to 30% of ARDS patients that could 
benefit from an additional Vt reduction.[5] In this scenario, extracorporeal lung support may play a 
role integrating conventional care and allowing the use of more protective ventilator settings.  The 
concept of removing “only a portion of carbon dioxide production”, originally developed by Pesenti 
et al., has been recently implemented in new devices that may reduce side effects, complexity, and 
costs of extracorporeal carbon dioxide removal.[30] 
Terragni e coll. managed effectively and safely respiratory acidosis consequent to Vt lower 
than 6 L/kg PBW and reestablished a normal arterial pH through extracorporeal carbon dioxide 
removal technique. The system, at 380 ml/min blood flow, could allow a PaCO2 reduction of 
approximately 20% at constant ventilation. [7] Therefore, the key for a revolutionary approach to 
ARDS ventilatory management, is shifting from invasive mechanical ventilation to the application 
of low extracorporeal blood flow combined with high efficiency ECCO2R as lung support. 
Venous blood contains large amounts of carbon dioxide, most carried as bicarbonate ion 
(approximately 500 ml/l of carbon dioxide under normocapnic conditions) and with a blood flow 
through the extracorporeal circuit of 500 ml/min, the tidal volume could be theoretically reduced to 
zero.  From these preliminary clinical data (waiting additional studies to further confirm these 
results), with the development of very efficient devices capable of removing a substantial amount of 
carbon dioxide production (30–100%) with blood flows of 250–500 ml/min we could assume the 
possibility of avoiding endotracheal intubation, with related complications like pulmonary 
infections and need of sedation.  In this way, severe ARDS patients could be managed without any 
form of mechanical ventilation, simply providing enough positive airway pressure to keep lung 
open and high FiO2 to avoid hypoxemia, as a bridge to recovery from the pulmonary disease. 
 
 
Conclusions 
With improved technology and experience, low extracorporeal blood flow with high performance 
ECCO2R may be the key to a new severe ARDS ventilator management, shifting from invasive 
mechanical ventilation to the application of extracorporeal lung support, similar to renal support. 
Lung protective ventilatory strategies with new solutions to remove CO2, might make clinicians 
rethink the role of extracorporeal lung support procedures in the treatment algorithm of ARDS. 
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